Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
Open accessAbstract
We used genome-wide methylation microarrays to analyze differences in CpG methylation patterns in cells relevant to the pathogenesis of myeloma plasma cells (B cells, normal plasma cells, monoclonal gammopathy of undetermined significance [MGUS], presentation myeloma, and plasma cell leukemia). We show that methylation patterns in these cell types are capable of distinguishing nonmalignant from malignant cells and the main reason for this difference is hypomethylation of the genome at the transition from MGUS to presentation myeloma. In addition, gene-specific hypermethylation was evident at the myeloma stage. Differential methylation was also evident at the transition from myeloma to plasma cell leukemia with remethylation of the genome, particularly of genes involved in cell–cell signaling and cell adhesion, which may contribute to independence from the bone marrow microenvironment. There was a high degree of methylation variability within presentation myeloma samples, which was associated with cytogenetic differences between samples. More specifically, we found methylation subgroups were defined by translocations and hyperdiploidy, with t(4;14) myeloma having the greatest impact on DNA methylation. Two groups of hyperdiploid samples were identified, on the basis of unsupervised clustering, which had an impact on overall survival. Overall, DNA methylation changes significantly during disease progression and between cytogenetic subgroups.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A notable decrease in methylation is the pivotal aspect of the shift from MGUS to MM.
“A notable decrease in methylation is the pivotal aspect of the shift from MGUS to MM.”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [139]
Methylation contributes to the advancement of the MM stage.
“Furthermore, it has been demonstrated that methylation contributes to the advancement of the MM stage.”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [139]
Cites
limma: Linear Models for Microarray Data
Smyth, G. K. (2005) · Statistics for Biology and Health · doi:10.1007/0-387-29362-0_23 · Cited by 5,796 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Walker, B. A., Wardell, C. P., Murison, A., Boyle, E. M., Begum, D. B., Dahir, N. M., Proszek, P. Z., Melchor, L., Pawlyn, C., Kaiser, M. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms7997 · Cited by 313 · see citing works
Self-citationBatch effect correction for genome-wide methylation data with Illumina Infinium platform
Sun, Z., Chai, H. S., Wu, Y., White, W. M., Donkena, K. V., Klein, C. J., Garovic, V. D., Therneau, T. M., & Kocher, J.-P. A. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-84 · Cited by 108 · see citing works
Ronchetti, D., Todoerti, K., Tuana, G., Agnelli, L., Mosca, L., Lionetti, M., Fabris, S., Colapietro, P., Miozzo, M., Ferrarini, M., et al. (2012) · Blood Cancer Journal · doi:10.1038/bcj.2012.41 · Cited by 79 · see citing works
Self-citationDrug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973836 · Cited by 65 · see citing works
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27 · see citing works
“Moreover, methylation changes take place during the malignant stages [139].”
- Authors
- Walker, B. A., Wardell, C. P., Chiecchio, L., Smith, E. M., Boyd, K. D., Neri, A., Davies, F. E., Ross, F. M., & Morgan, G. J.
- Affiliations
- Institute of Cancer Research (GB)
- Wessex Regional Genetics Laboratory (GB)
- University of Milan (IT)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-01-13
- Volume
- 117
- Issue
- 2
- Pages
- 553-562
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2127009065
- Cited by
- 267
- References
- 1
- Citations by year
- 2026: 3 · 2025: 15 · 2024: 8 · 2023: 13 · 2022: 16 · 2021: 21 · 2020: 19 · 2019: 15 · 2018: 23 · 2017: 14 · 2016: 17 · 2015: 21 · 2014: 20 · 2013: 24 · 2012: 21
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- Cancer Research UK
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- multiple myeloma, DNA methylation, CpG methylation, plasma cells, monoclonal gammopathy of undetermined significance, plasma cell leukemia, hypomethylation, hyperdiploidy, cytogenetics, disease progression, prognosis, overall survival, cell adhesion genes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Dexamethasone, Doxorubicin, Humans, Melphalan, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Prednisolone, Prognosis, Thalidomide, Vincristine, Cluster Analysis, In Situ Hybridization, Fluorescence, Disease Progression, DNA Methylation, Stem Cell Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review